LENSAR, Inc. (LNSR)
After hours:
| Previous close | 6.80 |
| Open | 6.90 |
| Bid | 6.86 x 900 |
| Ask | 7.00 x 1300 |
| Day's range | 6.83 - 7.00 |
| 52-week range | 6.13 - 9.83 |
| Volume | |
| Avg. volume | 8,457 |
| Market cap | 76.529M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 05 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.00 |
- Business Wire
LENSAR to Present at Two Upcoming Investor Conferences
ORLANDO, Fla., November 16, 2021--LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer will present at two upcoming investor conferences:
- Business Wire
LENSAR Announces Poster Presentations at the American Academy of Ophthalmology
ORLANDO, Fla., November 12, 2021--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that two posters have been accepted for virtual presentation at the Annual Meeting of the American Academy of Ophthalmology (AAO) being held November 12-15, 2021.
- Business Wire
LENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update
ORLANDO, Fla., November 08, 2021--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2021 and provided an update on key strategic and operational initiatives.
